Scale your Venture
invstt offers a chance to find the right investors to back your idea.
11-50
Bangalore
India , 2025
Bangalore
Our AI platform generates novel antibody therapeutics with predefined drug characteristics for any protein target, validated through in-house biological methods.
immunitoAI is a Tech-Bio company developing AI-generated, novel antibody therapeutics with predefined drug properties. We are an in-silico Antibody Discovery company and we use Artificial Intelligence and our in-house biological lab to give you the fastest and most accurate solutions. Our vision is to unleash the full potential of antibody-based biological drugs and make antibody therapy the norm.
* Biopharma defines the Disease and Target immunoAI will generate the antibody with the defined properties. * After experimental validation, the final drug candidates identified will be outlicensed to the pharma company. * Pharma takes up the pre-clinical and clinical studies for FDA approval. * Average Deal Size has been observed to be USD 300M, split across: - Upfronts (USD 10-50M). - Milestone-based payments at various stages. - Sales milestone. Additional royalty components applicable after sales app.
India
Marketplace
B2B, B2C
BigHat, absci, AbCellera, LabGenius, Adimab, Xaira, Aliva Mab, Nabla Bio, Antiverse
Set up your account as an Investor.
Already have an account? Login Nowinvstt offers a chance to find the right investors to back your idea.
Login and get access to a authentic community of investors, founders and professionals.